Topic:

R&D

Latest Headlines

Latest Headlines

Geron sinks as liver risks plague another imetelstat trial

A week after the FDA put a halt to Geron's in-house studies of the cancer drug imetelstat over toxicity concerns, the agency stepped in on a Mayo Clinic-run trial of the same treatment, citing familiar dangers and imposing a partial clinical hold.

Cancer gamification project analyzes 1.5M chromosomes in one month

Nonprofit Cancer Research UK is developing a good track record in gamification. In the 18 months since it introduced "Cell Slider," citizen scientists have analyzed more than two million images of tumor samples, and it is now reporting strong uptake of its new mobile game.

Imaging tech developer NinePoint nails a $34M Series B from Corning, Third Rock and Prospect

Corning is the lead investor in NinePoint Medical's newly nailed-down $34 million Series B round. The 2012 Fierce 15 winner and developer of a cutting-edge organ imaging system also convinced founding investors Third Rock Ventures and Prospect Venture Partners to take part in the company's latest financing.

Circassia begins trading in London following successful IPO

The first two days of trading passed uneventfully, with Circassia's stock fluctuating around the 310 pence ($5.20) per share price it commanded in the IPO to close on Wednesday at 309 pence.

MedImmune inks licensing deal with Bioasis for brain delivery platform

AstraZeneca's MedImmune forged a new deal with Bioasis Technologies, licensing from the Vancouver, Canada, company its brain delivery platform aimed at overcoming challenges associated with the blood-brain barrier.

Tamiflu study funded by Roche shows lives saved in pandemic

Governments around the world have been stockpiling Roche's Tamiflu to protect their citizens in the event of a flu pandemic--a practice that has been questioned by critics who say there's not enough evidence the drug works. Now, Roche has fresh data showing Tamiflu saved lives during the H1N1 swine flu outbreak of 2009.

Flagging Smiths Medical, soaring pound weigh down Smiths Group earnings

A British pound rising against the dollar cut into results at Smiths Group--but its U.S.-based Smiths Medical division, beset by competitors, led the bad-news story in the company's earnings report on the first half of its 2014 fiscal year.

Augmedix grabs $3.2M for Google Glass-enabled medical records physician tool

With Augmedix's new $3.2 million in venture funding, the use of Google Glass for healthcare gets a major boost. The San Francisco startup uses Google Glass technology to help doctors more efficiently push information to most electronic health records systems and also verbally seek information from them, according to the company's website.

C.R. Bard enrolls first patient in a new U.S. clinical trial of its drug-coated balloon

C.R. Bard enrolled its first patient in a new U.S. clinical trial of its drug-coated balloon. The technology could provide an alternative to traditional treatment methods for in-stent restenosis, the company said in a statement.

New incontinence data could give Ipsen's Dysport a path to lucrative urology use

Ipsen announced "positive results" in a Phase II trial of Dysport in patients with urinary incontinence. That could put Ipsen's drug in line for more head-to-head competition with Allergan's Botox, which has successfully expanded into several medical uses.